Mild Clinical Course of COVID-19 Infection in Chronic Myeloid Leukemia (CML) Patients Receiving Tyrosine Kinase Inhibitors (TKIs) without Interruption.
作者信息
Demeter Judit, Weisinger Julia, Nagy Zsolt
机构信息
Semmelweis University Department of Internal Medicine and Oncology, Division of Hematology; Budapest, Hungary.
出版信息
Mediterr J Hematol Infect Dis. 2021 Mar 1;13(1):e2021022. doi: 10.4084/MJHID.2021.022. eCollection 2021.
Abstract
摘要
相似文献
1
Mild Clinical Course of COVID-19 Infection in Chronic Myeloid Leukemia (CML) Patients Receiving Tyrosine Kinase Inhibitors (TKIs) without Interruption.接受酪氨酸激酶抑制剂（TKIs）且未中断治疗的慢性髓性白血病（CML）患者中COVID-19感染的临床过程较轻。
Mediterr J Hematol Infect Dis. 2021 Mar 1;13(1):e2021022. doi: 10.4084/MJHID.2021.022. eCollection 2021.
2
COVID-19 Impact on Chronic Myeloid Leukemia Patients.新冠病毒对慢性髓性白血病患者的影响。
J Pers Med. 2022 Nov 10;12(11):1886. doi: 10.3390/jpm12111886.
3
Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2.酪氨酸激酶抑制剂对慢性髓性白血病患者具有抗病毒作用：一种支持其用于抗击SARS-CoV-2的可能模型。
Front Oncol. 2020 Sep 2;10:1428. doi: 10.3389/fonc.2020.01428. eCollection 2020.
4
The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.酪氨酸激酶抑制剂对慢性髓性白血病干细胞的影响及其停药意义。
Stem Cells Dev. 2019 Nov 15;28(22):1480-1485. doi: 10.1089/scd.2019.0117. Epub 2019 Oct 22.
5
Current perspectives for the treatment of chronic myeloid leukemia.慢性髓性白血病治疗的现状。
Turk J Med Sci. 2019 Feb 11;49(1):1-10. doi: 10.3906/sag-1810-81.
6
Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia.ABL酪氨酸激酶抑制剂停止用于慢性髓性白血病研究的当前状况。
Stem Cell Investig. 2016 Aug 9;3:36. doi: 10.21037/sci.2016.07.08. eCollection 2016.
7
Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.骨髓间充质基质细胞通过 IL-7/JAK1/STAT5 通路促进慢性髓性白血病对酪氨酸激酶抑制剂的耐药性。
J Biol Chem. 2019 Aug 9;294(32):12167-12179. doi: 10.1074/jbc.RA119.008037. Epub 2019 Jun 24.
8
Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.患者及血液科医生对慢性髓性白血病酪氨酸激酶抑制剂治疗的担忧。
J Cancer Res Clin Oncol. 2018 Apr;144(4):735-741. doi: 10.1007/s00432-018-2594-8. Epub 2018 Jan 29.
9
Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.慢性髓性白血病患者酪氨酸激酶抑制剂停药相关的焦虑和抑郁。
Int J Clin Oncol. 2018 Oct;23(5):974-979. doi: 10.1007/s10147-018-1275-6. Epub 2018 Apr 12.
10
The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.Fas相关磷酸酶1在慢性髓性白血病酪氨酸激酶抑制剂治疗期间白血病干细胞持续存在中的作用
Leukemia. 2016 Jul;30(7):1502-9. doi: 10.1038/leu.2016.66. Epub 2016 Mar 17.
引用本文的文献
1
Recent Advances in Serum Biomarkers for Cardiological Risk Stratification and Insight into the Cardiac Management of the Patients With Hematological Malignancies Treated With Targeted Therapy.用于心脏病风险分层的血清生物标志物的最新进展以及对接受靶向治疗的血液系统恶性肿瘤患者心脏管理的见解。
Cureus. 2023 Nov 30;15(11):e49696. doi: 10.7759/cureus.49696. eCollection 2023 Nov.
2
Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection-A Single Center Survey.慢性髓性白血病合并 COVID-19 感染患者的临床结局：一项单中心调查。
Medicina (Kaunas). 2023 Aug 28;59(9):1564. doi: 10.3390/medicina59091564.
3
COVID-19 Impact on Chronic Myeloid Leukemia Patients.新冠病毒对慢性髓性白血病患者的影响。
J Pers Med. 2022 Nov 10;12(11):1886. doi: 10.3390/jpm12111886.
4
What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?目前我们对慢性髓性白血病（CML）和 COVID-19 了解多少？
Curr Oncol Rep. 2022 May;24(5):645-650. doi: 10.1007/s11912-021-01169-w. Epub 2022 Feb 26.
本文引用的文献
1
SARS CoV 2 infection in chronic myelogenous leukemia: Severe hematological presentation.慢性髓性白血病中的新型冠状病毒2型感染：严重血液学表现。
Transfus Apher Sci. 2020 Dec;59(6):102881. doi: 10.1016/j.transci.2020.102881. Epub 2020 Jul 23.
2
Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary.匈牙利人群中的新型冠状病毒疫情，一项支持匈牙利退出政策的全国性横断面调查。
Geroscience. 2020 Aug;42(4):1063-1074. doi: 10.1007/s11357-020-00226-9. Epub 2020 Jul 17.
3
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey.意大利新冠疫情期间慢性髓系白血病的管理。一项校园慢性髓系白血病调查。
Leukemia. 2020 Aug;34(8):2260-2261. doi: 10.1038/s41375-020-0904-z. Epub 2020 Jun 18.
4
COVID-19 in persons with chronic myeloid leukaemia.新型冠状病毒肺炎在慢性髓性白血病患者中的情况。
Leukemia. 2020 Jul;34(7):1799-1804. doi: 10.1038/s41375-020-0853-6. Epub 2020 May 18.
5
SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.严重急性呼吸综合征冠状病毒2（新冠病毒）与慢性髓性白血病：1例病例报告及ABL激酶在病毒感染中的作用综述
Mediterr J Hematol Infect Dis. 2020 May 1;12(1):e2020031. doi: 10.4084/MJHID.2020.031. eCollection 2020.
6
Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.阿贝尔森激酶抑制剂是严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒融合的强效抑制剂。
J Virol. 2016 Sep 12;90(19):8924-33. doi: 10.1128/JVI.01429-16. Print 2016 Oct 1.
Zotero 插件